The significance of MUM1/IRF4 protein expression and IRF4 translocation of CD30(+) cutaneous T-cell lymphoproliferative disorders: A study of 53 cases

Leukemia Research

Volumn 37, Issue 4, 2013, Pages 396-400

  Kiran, Tugce ^a   Demirkesen, Cuyan ^a   Eker, Candan ^b   Kumusoglu, Hakki ^b   Tuzuner, Nukhet ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Medimiks Medical Biotechnology   (Turkey)

Author keywords

ALCL; CD30; Cutaneous lymphomas; IRF4 translocation; MUM1

Indexed keywords

CD30 ANTIGEN; DNA; INTERFERON REGULATORY FACTOR 4;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MYCOSIS FUNGOIDES; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; SKIN BIOPSY;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD30; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INTERFERON REGULATORY FACTORS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; PROTEIN TRANSPORT; SKIN NEOPLASMS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 84875381726     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.12.001     Document Type: Article

References (11)

1. Feldman A.L., Law M., Remstein E.D., et al. Recurrent translocations involving the IRF4 oncogene locus in peripheral T-cell lymphomas. Leukemia 2009, 23(March (3)):574-580.
2. Falini B., Fizzotti M., Pucciarini A., et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood 2000, 95(March (6)):2084-2092.
3. Wada D.A., Law M.E., Hsi E.D., et al. Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies. Mod Pathol 2011, 24(April (4)):596-605.
4. Pham-Ledard A., Prochazkova-Carlotti M., Laharanne E., et al. IRF4 gene rearrangements define a subgroup of CD30-positive cutaneous T-cell lymphoma: a study of 54 cases. J Invest Dermatol 2010, 130(March (3)):816-825.
5. Feldman A.L., Dogan A., Smith D.I., et al. Discovery of recurrent t(6;7) (p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood 2011, 117(January (3)):915-919.
6. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC Press, Lyon, France. 4th ed.
7. Kempf W., Kutzner H., Cozzio A., et al. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br J Dermatol 2008, 158:1280-1287.
8. Wasco M.J., Fullen D., Su L., Ma L. The expression of MUM1 in cutaneou T-cell lymphoproliferative disorders. Hum Pathol 2008, 39:557-563.
9. Benner M.F., Jansen P.M., Meijer C.J., Willemze R. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1 BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br J Dermatol 2009, 161:121-127.
10. Hernandez-Machin B., de Misa R.F., Montenegro T., et al. MUM1 expression does not differentiate primary cutaneous anaplastic large-cell lymphoma and lymphomatoid papulosis. Br J Dermatol 2009, 160:173.
11. Shaffer A.L., Emre N.C.T., Romesser P.B., Staudt L.M. IRF4: immunity malignancy! therapy?. Clin Cancer Res 2009, 15:2954-2961.